Increased mortality after dronedarone therapy for severe heart failure
about
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillationAtrial fibrillation in heart failure: what should we do?European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyAntiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safetyThe role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLASAtrial fibrillation therapy now and in the future: drugs, biologicals, and ablationDronedarone-current status in management of atrial fibrillationAtrial fibrillation in heart failure: an innocent bystander?An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillationClinical and genetic determinants of torsade de pointes risk2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Rationale and current perspective for early rhythm control therapy in atrial fibrillation.Atrial Electrophysiological Remodeling and Fibrillation in Heart FailureThe current approach of atrial fibrillation management2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theManagement Of Atrial Fibrillation In Patients With Heart FailureWho Needs Pharmacologic Therapy?Lone atrial fibrillation: where are we now?2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.Management of ventricular tachycardia in heart failure.Chronic heart failure: contemporary diagnosis and managementAntiarrhythmic drugs for atrial fibrillation.Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Current and emerging antiarrhythmic drug therapy for ventricular tachycardiaEffects of neferine on the pharmacokinetics of amiodarone in rats.Dronedarone in patients with congestive heart failure: insights from ATHENA.Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation.Rate versus rhythm control in atrial fibrillation.Advances in the Pharmacological Treatment of Atrial Fibrillation.Present concepts in management of atrial fibrillation: From drug therapy to ablation.Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure.Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditisDéjà vu in the theories of atrial fibrillation dynamics.A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention.Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.
P2860
Q24187110-1A982E79-1E23-4B1B-9799-F6F1691CDC52Q26784426-BA29C9F1-2C73-4EF7-BDCE-A89668707EC1Q26796261-691B7F3E-868F-40A1-AA25-3AA6B8AC3D4EQ26852003-5E386BC1-2D61-48F8-9EB7-AA647CDFF087Q26853369-32B7F557-D14C-4295-AD89-94E476838A9FQ26864767-C30772C8-F6FF-4611-AA2C-54B9CE74E10FQ27001666-C0406DF9-4194-435A-83C1-7943B7B3F751Q27010588-E72AD922-4252-43B6-B857-B07C4AD67712Q27011828-1392460E-5871-4A4E-9BB2-8777CE8CD800Q27014821-DD8ED128-D0FF-4D94-9E8F-BF59A5E6AB8DQ27341873-570D9B90-BA37-4809-9D94-9314443A88A3Q27692632-8BC2B5D2-4118-4E7B-B206-1F61B1B66563Q28066307-B4265001-8417-4092-B010-1969FEBDD897Q28076171-1A3DFBEB-D61C-47FF-8112-1E8278CBCFC2Q28087002-3717DB91-A8B3-488B-A137-B3E9FE7B07CCQ30354835-3E49A5D6-3479-4500-AB54-BAF6994F6718Q30354838-167B920C-DE02-40D0-B7BB-4A47235D5375Q30409016-FAFFF886-A435-4FF7-BBD0-9A18921CD098Q30653045-1632403F-8DF5-4C41-A3FE-C13D62193AB9Q33162550-159E82C7-88C1-4ED2-81E8-9AA3546797AFQ33620431-20324B9C-3C53-46F2-8903-454359212501Q33821199-E996B3F5-8FC7-439D-95FB-6C135447B907Q33902193-02AF8762-43F9-4212-8D61-9E394A7AB6D7Q33936131-92325370-DE39-4008-A56F-5B0B22568577Q33950584-C51E7907-970C-4066-BA65-A847C631DB16Q33992727-ADD4B910-E2B3-4786-9C08-0FB857CBD48CQ34068720-4E636407-DC32-41CC-8980-9E017A751850Q34068742-8D039451-2D65-4047-83CF-A22ABD972C15Q34181734-D09E465F-1DAA-4ADF-BEB1-41FF182BEFF9Q34239793-6742C4F8-5069-4574-9EB6-C50BCFDFC38DQ34328299-BFC574C6-15CB-4903-A3A5-FB8C5F6B36C3Q34383573-391832D4-65D7-44FE-AF60-040EDAE231CDQ34389483-B31BD285-E775-45A9-86F6-E33D309C0B71Q34502114-FBDD9AF0-EC2E-4577-8F4F-2B5CA380E8F6Q34634617-B108D420-ECED-4748-8E14-B9B12075178CQ34810800-63D55D83-69B9-4C88-B936-2F1CE8587844Q35018357-57C258E7-C572-4557-9EAA-17DEE0AEE435Q35139947-F48A704D-93EE-4A8C-AADB-2DD8B47FEB29Q35209970-0F5D0A78-33CA-40D2-AF46-8C6EDF6188B3Q35440513-3773C2C7-C697-44EE-8988-0C4D6D568469
P2860
Increased mortality after dronedarone therapy for severe heart failure
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Increased mortality after dronedarone therapy for severe heart failure
@ast
Increased mortality after dronedarone therapy for severe heart failure
@en
Increased mortality after dronedarone therapy for severe heart failure
@nl
type
label
Increased mortality after dronedarone therapy for severe heart failure
@ast
Increased mortality after dronedarone therapy for severe heart failure
@en
Increased mortality after dronedarone therapy for severe heart failure
@nl
prefLabel
Increased mortality after dronedarone therapy for severe heart failure
@ast
Increased mortality after dronedarone therapy for severe heart failure
@en
Increased mortality after dronedarone therapy for severe heart failure
@nl
P2093
P3181
P356
P1476
Increased mortality after dronedarone therapy for severe heart failure
@en
P2093
Harry Crijns
Jan Carlsen
John J V McMurray
Ole Gøtzsche
Samuel Lévy
P304
P3181
P356
10.1056/NEJMOA0800456
P407
P577
2008-06-19T00:00:00Z